Durable clinical responses to immune checkpoint inhibitors (ICB) remain limited to a minority of patients, and the molecular pathways that modulate ICB efficacy remain incompletely defined. Here we demonstrate that immunotherapy with anti-CTLA-4 and its combination with anti-PD-1 rely on melanoma cell-intrinsic activation of the cytosolic RNA receptor RIG-I. Mechanistically, tumor cell-intrinsic RIG-I...

This dataset contains summary data visualizations and clinical data from a broad sampling of 1,661 samples of across multiple cancer types showing tumor mutational load and survival following immunotherapy from 1,661 patients. The data was gathered utilizing the MSK-IMPACT targeted sequencing test. The clinical data includes tumor type (based on the opensource OncoTree ontology developed at MSK),...

This dataset contains summary data visualizations and clinical data from 67 samples from 67 patients as part an NCI-60 cell line project to compile NCI-60 cell line high-throughput and high-content data into CellMiner, a genomic and pharmacologic database created by the National Cancer Center Institute. The clinical data includes deidentified patient and sample IDs, mutation counts, detailed cancer...

TCGA Skin Cutaneous Melanoma. Source data from GDAC Firehose. Previously known as TCGA Provisional. This dataset contains summary data visualizations and clinical data from a broad sampling of 480 carcinomas from 471 patients. The data was gathered as part of the Broad Institute of MIT and Harvard Firehose initiative, a cancer analysis pipeline. The clinical data includes mutation count, information...

Summary from the GEO: "Immune checkpoint blockade (ICB) has demonstrated significant promise for the treatment of advanced malignancies. Anti-CTLA4 and ant-PD1 therapy can activate the immune system and result in durable control in diseases such as melanoma and non-small cell lung cancer. 109 RNASeq samples (58 On-treatment and 51 Pre-treatment) from 65 patients." Abstract from the publication that...

Summary from the GEO: "We report how the A375 melanoma cell line changes following CRISPR-Cas9 inactivation of POLK RNA-seq of A375 melanoma cells following CRISPR-Cas9 with either POLK sgRNA or non-targeting control sgRNA (N=3 replicate samples each)." Abstract summary From "Regulation of the error-prone DNA polymerase Polκ by oncogenic signaling and its contribution to drug resistance": "The DNA...

Summary from BioProject: "Tumors with mismatch repair deficiency (MMR-d) are characterized by sequence alterations in microsatellites and can accumulate thousands of mutations across the genome. This high mutational burden renders these tumors immunogenic and sensitive to PD-1 blockade. However, despite the immunogenicity of these tumors, clinical responses are highly variable, and many patients with...

This dataset contains the summary data visualizations and clinical data of whole-exome sequencing of 64 pretreated melanoma tumor-normal pairs in 64 patients. Clinical data includes:Cancer Type, Mutation Count, Fraction Genome Altered, Age at Diagnosis, Sex, Tumor Site, Biopsy Time, CBSET B cells memory, CBSET B cells naive, CBSET Dendritic cells activated, CBSET Dendritic cells resting, CBSET Eosinophils,...

This dataset contains the summary data visualizations and clinical data of Exome/Whole Genome sequencing of 20 desmoplastic melanoma tumor/normal pairs. Clinical data includes: Mutation Count, Diagnosis Age, Anatomic Region, Detailed Sample Histology Category, Platform, Secondary Platform, Total Mutations, and Tumor Other Histologic Subtype. The plaintext components of the dataset can be downloaded...

This dataset contains the summary data visualizations and clinical data of targeted sequencing of 66 pre-treatment melanoma tumor samples from 66 patients. Clinical data includes: Mutation Count, Metastasis/Primary Sample Type, Agent Used, BORR, BRAIN METS, Chemotherapy, ECOG Status, Immunotherapy, Liver Involvement, M Stage, Number of Sites, Progress Free Survival (Months) . The plaintext components...